A Warning Letter Trend Surprise: Good In India, Bad In South Korea

 
• By Bowman Cox

A comparison of US FDA inspection and warning letter rates find India performs much better than China and South Korea.

Asia - Pacific
where asia-pacific drug quality issues are actually concentrated

More from Manufacturing

More from Compliance